Tenaya Therapeutics is trading 5.16% up now at $0.71, outperforming the prior close of $0.67 amid broader biotechnology strength.
- XBI was up 2.55% during regular trading, making sector strength the most consistent explanation for the move.
- No new company-specific announcement, filing, or analyst action dated September 18, 2026, was identified.
- The latest prominent catalyst was the September 14 FDA RMAT designation for TN-401.